Patents Examined by Zachary Howard
  • Patent number: 10053515
    Abstract: Antibodies that bind the apple 2 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa are described.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: August 21, 2018
    Assignees: Merck Sharp & Dohme Corp., Adimab LLC
    Inventors: Zhu Chen, Kenneth P. Ellsworth, James A. Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard, Bianka Prinz
  • Patent number: 10046011
    Abstract: The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).
    Type: Grant
    Filed: December 14, 2013
    Date of Patent: August 14, 2018
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Yufang Shi, Guangwen Ren, Liying Zhang
  • Patent number: 10035854
    Abstract: The invention provides anti-LRP5 antibodies and methods of making and using the same.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: July 31, 2018
    Assignee: GENENTECH, INC.
    Inventors: Yan Wu, Weilan Ye, Jeremy Bryant Burton, Cecilia Chiu
  • Patent number: 10023621
    Abstract: The disclosure provides, in part, follistatin polypeptides that are suitable for use in local administration and methods for use.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: July 17, 2018
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg
  • Patent number: 10010498
    Abstract: The disclosure provides, in part, follistatin polypeptides that are suitable for use in local administration and methods for use.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: July 3, 2018
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg
  • Patent number: 10004754
    Abstract: A therapeutic method for treating and/or preventing diseases and medical conditions typically treated by administering diuretic agents (eg congestive heart failure). The method may comprise, for example, administering to a subject a diuretic agent in combination with vessel dilator (VSDL) or a variant or modified peptide thereof. The administration of the diuretic agent may be a component of a standard of care (SOC) treatment.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: June 26, 2018
    Assignee: Madeleine Pharmaceuticals Pty Ltd.
    Inventor: Thomas Robert Geimer
  • Patent number: 9995748
    Abstract: The disclosure provides methods of using biomarkers to improve diagnosis of forms of prostate. The method includes testing a biological sample from an individual for a interleukin-8 (IL-8), Tumor necrosis factor alpha (TNF-a) and soluble tumor necrosis factor-? receptor 1 (sTNFR1), and may further include testing for prostate serum antigen (PSA). Use of these markers in combination provides tests that are more sensitive and specific than PSA in differentiating benign versus malignant prostate disease and/or localized CaP versus metastatic CaP and show that the specificity and sensitivity of a PSA-based CaP diagnosis can be significantly enhanced by measuring IL-8, TNF-a and sTNFR1.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: June 12, 2018
    Assignee: Health Research, Inc.
    Inventors: Kailash Chadha, Willie Underwood, Austin Miller
  • Patent number: 9993516
    Abstract: The present disclosure provides methods and compositions for treatment of left ventricular non-compaction and dilated cardiomyopathies.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: June 12, 2018
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Calum Macrae, Anne-Karin Kahlert
  • Patent number: 9987327
    Abstract: The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: June 5, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER, ASSITANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, UNIVERSITE D'ANGERS
    Inventors: Alain Lacampagne, Jerome Thireau, Olivier Cazorla, Jean-Yves Le Guennec, Jeremy Fauconnier, Maria del Carmen Martinez, Ramaroson Andriantsitohaina, Bijan Ghaleh-Marzban, Raffaella Soleti
  • Patent number: 9988455
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: June 5, 2018
    Assignee: NOVARTIS AG
    Inventors: Kurt Alex Heldwein, Jennifer Brogdon, William Dole, John Trauger, Yuting Tang, Julia Neugebauer, Annika Schmid
  • Patent number: 9989531
    Abstract: Methods of stratifying a subject having or at risk for developing adolescent idiopathic scoliosis (AIS) into diagnostically or clinically useful subclasses are provided. The stratification is based on the subject's PTP? expression and/or activity and/or PIPK1? expression and/or activity. Also provided are methods of predicting the risk of developing a scoliosis also based on the subject's PTP? expression and/or activity and/or PIPK1? expression and/or activity; and methods of increasing GiPCR signaling in cells of a subject in need thereof comprising administering to the subject's cells an effective amount of an inhibitor of PIPK1? tyrosine phosphorylation; an activator of PIPK1Y tyrosine dephosphorylation; and/or an inhibitor of PIPK1? expression and/or activity.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: June 5, 2018
    Assignee: Chu Sainte-Justine
    Inventors: Alain Moreau, Marie-Yvonne Akoume Ndong, Mohamed Elbakry
  • Patent number: 9980960
    Abstract: A method for determining the risk of cardiovascular disease in a subject having a chronic viral infection includes determining a level of ectonucleotide pyrophosphatase/phosphodiesterase-2 (ENPP2) in the subject and comparing the determined level of ENPP2 to a control level, wherein an increased level of ENPP2 is indicative of the subject having an increased risk of cardiovascular disease associated with the chronic viral infection.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: May 29, 2018
    Assignee: Case Western Reserve University
    Inventor: Mark R. Chance
  • Patent number: 9983213
    Abstract: The present invention relates to a method for identifying a subject being susceptible to anti-angiogenesis therapy based in determining the amount of a cardiac troponin in a sample of the subject and comparing the amount to a suitable reference amount. Also encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: May 29, 2018
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Georg Hess, Andrea Horsch, Dietmar Zdunek
  • Patent number: 9982046
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: May 29, 2018
    Assignee: NOVARTIS AG
    Inventors: Kurt Alex Heldwein, Igor Splawski, Jennifer Brogdon, Joshua Goldstein, William Dole, John Trauger, Chonghui Zhang
  • Patent number: 9975962
    Abstract: This disclosure provides protease-regulated antibodies which specifically bind to tissue factor pathway inhibitor (TFPI). The antibodies are useful for treating bleeding disorders such as hemophilia.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 22, 2018
    Assignee: BAYER HEALTHCARE LLC
    Inventors: Zhuozhi Wang, Ruth Winter, John Murphy
  • Patent number: 9975934
    Abstract: In certain aspects, the present disclosure provides compositions and methods for inhibiting activity of TGF? superfamily ligands, particularly ligands such as GDF8, GDF11, activin A, activin B, activin C and activin E, in vertebrates, including rodents and primates, and particularly in humans. In some embodiments, the compositions of the disclosure may be used to treat or prevent diseases or disorders that are associated with abnormal activity of a follistatin-related polypeptide and/or a follistatin ligand.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: May 22, 2018
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne S. Sako
  • Patent number: 9962427
    Abstract: A method is disclosed for inducing right ventricular (RV) adaptive remodeling in a patient suffering from pulmonary hypertension (PH) due to pressure overload comprising administering a therapeutically effective amount of a carditrophin-1 polypeptide, recombinant protein or a polynucleotide encoding CT-1 polypeptide or full-length protein.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: May 8, 2018
    Assignee: Ottawa Hospital Research Institute
    Inventors: Colin Suen, Lynn Megeney, Duncan J. Stewart, Mohammad Abdul-Ghani
  • Patent number: 9957309
    Abstract: The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of a recombinant follistatin protein such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: May 1, 2018
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventor: Rochelle Mineau
  • Patent number: 9952213
    Abstract: It is intended to evaluate an ischemic heart disease with high accuracy by convenient operation. The method for evaluating an ischemic heart disease according to the present invention comprises the steps of: assaying complement factor H and/or complement factor D in a sample derived from the blood of a test subject; and comparing the concentration of the complement factor H and/or the concentration of the complement factor D assayed in the preceding step with a reference value(s), wherein it is determined that the seriousness of the ischemic heart disease is high when the concentration falls below the reference value.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: April 24, 2018
    Assignee: HITACHI, LTD.
    Inventors: Hiroko Hanzawa, Takeshi Sakamoto, Yuji Kuge
  • Patent number: 9932393
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of renal damage. The invention provides protein-based renal therapeutic agents for administration to subjects in order to prevent or treat renal degeneration or damage.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: April 3, 2018
    Assignee: Stowers Institute for Medical Research
    Inventors: Robb Krumlauf, Debra Ellies